Pharmaceutical Executive Daily
New research suggests Ozempic may reduce biological age.
In today's Pharmaceutical Executive Daily, we cover the FDA approval of Bayer's Lynkuet for menopausal hot flashes and Novartis' $12 billion merger agreement to acquire Avidity Biosciences.
- The FDA has approved Bayer's Lynkuet, also known as elinzanetant, as the first dual neurokinin 1 and 3 receptor antagonist for the treatment of moderate to severe vasomotor symptoms associated with menopause.
- The approval is based on Phase III OASIS trial data showing significant reductions in hot flash frequency and severity.
- Lynkuet provides an important new therapeutic alternative for patients seeking relief from menopausal symptoms without estrogen exposure.
Author's summary: New research on Ozempic and FDA approval of Lynkuet.